{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:58:46Z","timestamp":1760061526665},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,12,15]],"date-time":"2006-12-15T00:00:00Z","timestamp":1166140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paricalcitol capsules are indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease (CKD). Proton pump inhibitors are prescribed to CKD patients to treat gastroesophageal reflux. This was a single dose, crossover study evaluating the effect of omeprazole, change in gastric pH as a result thereof, on the pharmacokinetics (PK) of paricalcitol. Twenty\u2010six healthy subjects were administered paricalcitol capsules (16 \u00b5g) alone (regimen A), and following a single dose of OMP (40 mg) (regimen B), with a washout of at least 7 days. Plasma samples for paricalcitol concentrations were collected for 48 h post\u2010paricalcitol dose. The plasma paricalcitol concentrations were measured using an LC\u2013MS\/MS assay (LOQ=0.02 ng\/ml) and paricalcitol pharmacokinetic parameters were estimated using non\u2010compartmental methods. The point estimates and the corresponding 90% confidence intervals for <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>AUC<\/jats:italic><jats:sub>0\u2010\u221e<\/jats:sub> to evaluate paricalcitol\u2013omeprazole interaction were 1.032 [0.920\u20131.158] and 1.041 [0.951\u20131.139], respectively. No significant differences in <jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub> (regimen A: 2.9 h vs regimen B: 2.6 h) or <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> (6.83 h vs 6.6 h) between the regimens were observed. Hence, the co\u2010administration of omeprazole does not affect the PK of paricalcitol. Both regimens were well tolerated and no apparent differences among the regimens with respect to safety were observed. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.532","type":"journal-article","created":{"date-parts":[[2006,12,15]],"date-time":"2006-12-15T17:47:18Z","timestamp":1166204838000},"page":"65-71","source":"Crossref","is-referenced-by-count":5,"title":["Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects"],"prefix":"10.1002","volume":"28","author":[{"given":"Rameshraja","family":"Palaparthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra S.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Rieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titus","family":"Chira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Galitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Awni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,18]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"770A","article-title":"Assessment of the absolute bioavailability and food effect of paricalcitol capsule (ZemplarTM) in healthy adults","volume":"12","author":"Pradhan R","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_3_2","first-page":"770A","article-title":"Assessment of dose proportionality of paricalcitol capsule (ZemplarTM) in healthy adults","volume":"12","author":"Pradhan R","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_1_4_2","article-title":"Single and multiple dose safety and pharmacokinetic assessment of paricalcitol (Zemplar\u00ae) capsule following daily (qd) and three\u2010times\u2010a\u2010week dosing in healthy subjects","volume":"4","author":"Palaparthy R","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01307542"},{"key":"e_1_2_1_6_2","first-page":"461","article-title":"Gastrointestinal function, morphology, and immune status in uremia","volume":"6","author":"el\u2010Lakany S","year":"1990","journal-title":"Nutrition"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01210.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5831.22"},{"key":"e_1_2_1_9_2","unstructured":"Prilosec (omeprazole) Package Insert (Label) Astra Zeneca Inc.http:\/\/www.astrazeneca\u2010us.com\/pi\/prilosec\/plcoated.pdf."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00266355"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835020-00003"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.114231"},{"key":"e_1_2_1_13_2","first-page":"567","article-title":"Omeprazole weakly inhibits CYP1A2 activity in man","volume":"37","author":"Rost KL","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_14_2","volume-title":"Coding Symbols for Thesaurus of Adverse Reaction Terms"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199121030-00004"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.532","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T21:07:37Z","timestamp":1699996057000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,18]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1002\/bdd.532"],"URL":"https:\/\/doi.org\/10.1002\/bdd.532","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,18]]}}}